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The nucleocapsid (N) protein is a structural component of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) and can induce
antibody responses in SARS patients during infection. However, it is not known whether SARS-CoV N protein can induce a long persistence of
memory T-cell response in human. In this study, we found that peripheral blood mononuclear cells (PBMCs) from fully recovered SARS
individuals rapidly produced IFN-γ and IL-2 following stimulation with a pool of overlapping peptides that cover the entire N protein sequence.
The N-specific IFN-γ+CD4+ T cells were mainly composed of CD45RA−CCR7+CD62L− cells, whereas IFN-γ+CD8+ memory T cells were
mostly contained within CD45RA+CCR7−CD62L− cell population. Epitope mapping study indicated that a cluster of overlapping peptides located
in the C-terminal region (amino acids [aa] 331 to 362) of N protein contained at least two different T-cell epitopes. The results indicated that
human memory T-cell responses specific for SARS-CoV N protein could persist for 2 years in the absence of antigen, which would be a valuable
for the design of effective vaccines against SARS-CoV and for basic studies of human T-cell memory.
© 2006 Elsevier Inc. All rights reserved.Keywords: Severe acute respiratory syndrome (SARS); N protein; Memory T cells; EpitopeIntroduction
At the end of 2002, severe acute respiratory syndrome
(SARS) emerged as a new epidemic form of life-threatening
infectious disease (Drosten et al., 2003; Peiris et al., 2003).
More than 8400 individuals were infected, and 800 of them died
in approximately 7 months over 30 countries. The causative
agent of severe acute respiratory syndrome (SARS) was
identified as a new type of coronavirus, SARS coronavirus
(SARS-CoV) (Falsey and Walsh, 2003; Peiris et al., 2003;
Tsang et al., 2003). Although the first SARS epidemic has been
successfully controlled, SARS still remains a potential threat to
humans because the pathogenesis of SARS is not well⁎ Corresponding author. Fax: +86 20 87331552.
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doi:10.1016/j.virol.2006.03.036understood and no effective approaches to prevent and treat
the disease are developed.
As we know, SARS-CoV is a positive-sense RNA virus and
the virion consists of a nucleocapsid core surrounded by an
envelope containing three membrane proteins, spike (S),
membrane (M) and envelope (E) (Marra et al., 2003; Tan et
al., 2004). The N protein of CoV is a structural component of
the helical nucleocapsid and plays an important role in viral
pathogenesis, replication and RNA packaging (Hiscox et al.,
2001; Narayanan et al., 2003). Furthermore, this protein is more
conserved than other proteins of the virus, such as spike and
membrane glycoproteins. Among all the coronavirus proteins,
the N protein is the most abundant throughout infection at both
mRNA and protein levels (Hiscox et al., 2001). Previous studies
have shown that the N protein is one of the immunodominant
antigens in the CoV family (Boots et al., 1992; Stohlman et al.,
1994; Wesseling et al., 1993). In addition, it has been proved
Fig. 1. Production of IFN-γ by PBMCs from SARS-recovered individuals
induced with a pool of SARS-CoV N peptides. (A) PBMCs from seven SARS-
recovered donors were cultured in 96-well plates with or without a pool of N
peptides for 72 h. The culture supernatants were collected and assessed for the
production of IFN-γ by ELISA. All of assays were performed in triplicate.
Statistical analysis used a Student's t test. Statistical significant difference was
set at P < 0.05(**). *P > 0.05. Bars indicate mean values. (B) PBMCs from
eleven SARS-recovered donors were stimulated with a pool of N peptides. IFN-
γ-producing cells were detected by ELIspot assay. PBMCs incubated with
medium alone were used as negative controls. The number of spots in the
medium control wells ranged from 0 to 2. All of assays were performed in
triplicate. Statistical analysis used a Student's t test. Statistical significant
difference was set at P < 0.05(**). *P > 0.05. Bars represent mean values.
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coronavirus can generate protective effects (Collisson et al.,
2000; Stohlman et al., 1995). Recently, several studies in
animals demonstrated that the SARS-CoV N could induce
specific T-cell responses (Gao et al., 2003; Jin et al., 2005; Kim
et al., 2004, Zhu et al., 2004), as have been observed with other
coronaviruses. Therefore, N protein may be an important target
for SARS vaccine.
Evidence suggests that the most effective prevention method
against a pathogen is vaccination. Immunological memory is
the basis of vaccination. At present, most studies of immune
memory after SARS-CoV infection focused on memory B cells.
It is clear that antibody responses specific to SARS-CoV has
been observed in all of SARS patients (Li et al., 2003) and can
last up to 540 days after the onset of symptoms (Mo et al.,
2005). However, little is known about the memory T
lymphocyte responses in human SARS-CoV infection.
To explore the persistence and quality of T-cell memory to
SARS-CoV in human, we investigated SARS-CoV N-protein-
specific memory T-cell response in a group of Chinese
individuals who had clinical infections with SARS-CoV
2 years earlier. We were able to demonstrate that SARS-CoV
N-protein-specific memory CD4+ and CD8+ T cells were
existed in all SARS donors and maintained for 2 years in the
absence of pathogen. Furthermore, we report the detailed
mapping of T-cell epitopes using an overlapping peptide library
spanning the entire N protein. These results provide critical
information for the design of effective vaccines against SARS-
CoV and for basic studies of human T-cell memory.
Results
Memory T-cell response specific for SARS-CoV N protein
persists for 2 years after recovery
To identify memory T-cell response to N protein after SARS-
CoV infection in humans, PBMCs from seven individuals who
had fully recovered from SARS 2 years after infection were
stimulated with a pool of 57 peptides spanning the entire amino
acid sequence of the N protein in vitro for 72 h. The culture
supernatants were collected for detection of IFN-γ by ELISA.
As shown in Fig. 1A, although the level of IFN-γ varied from
donor to donor (ranged from 54 to 230 pg/ml), all of SARS-
recovered donors were capable of producing IFN-γ in response
to N peptides. However, the levels of IFN-γin normal
individuals were less than 25 pg/ml.
Next, we determined the frequency of N-protein-specific T
cells by using IFN-γ ELIspot assay. Fig. 1B showed that the
PBMCs from all of the 11 SARS-recovered individuals tested
displayed significantly higher frequency of IFN-γ-producing
cells than those from normal donors after stimulation with a
pool of N peptides. The frequency of IFN-γ-producing cells
from SARS-recovered individuals was at 63 SFC/million
PBMCs, with a range of 10–178 SFC/million PBMCs. It is
also noticed that there was no obvious difference in the
frequencies of IFN-γ-producing T cells of the SARS donors and
normal controls when PBMCs were stimulated with anti-CD3and anti-CD28 mAbs (data not shown). These results
demonstrated that the N protein of SARS-CoV was highly
immunogenic and N-protein-specific T-cell responses could
persist at least for 2 years after SARS-CoV infection.
Characterization of long-term memory T cells specific for N
protein
To assess the cell populations involved in the N-specific T-
cell response, PBMCs from six SARS-recovered donors were
incubated with a pool of N peptides and stained for cell surface
and intracellular IFN-γ expression (Fig. 2). The results showed
that IFN-γ-producing CD8+ T cells specific to N protein were
detected in all of the SARS-recovered donors with a mean
frequency of 0.132% (range: 0.06%–0.23%). However, the
Fig. 2. Detection of IFN-γ-producing T cells specific to SARS-CoV N peptides
by intracellular staining. PBMCs from SARS-recovered donors were incubated
with a pool of peptides for 6 h. Cell surface and intracellular cytokine staining
for IFN-γ was performed. The cells were first gated on CD4−CD8+ T cells (A)
and CD8−CD4+ T cells (B) and analyzed for IFN-γ expression. Results shown
are from one experiment performed on PBMC from a SARS patient and are
representative of 5 independent experiments from 5 SARS patients. C represents
the expression of IFN-γ as percentage of total CD4+ or CD8+ T cells in different
patients. Bars indicate mean values.
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protein was lower than that of CD8+ T cells (mean: 0.072%,
range: 0.05%–0.10%). These results demonstrated that both
CD4+ and CD8+ T cells were involved in SARS-CoV N-
specific immune responses and that CD8+ T cells were the
major component of T-cell responses to SARS-CoV N-specific
antigen.
Besides studying IFN-γ, the function of memory T cells was
also evaluated on the basis of their ability to secrete IL-2 by
flow cytometry. In this experiment, PBMCs from SARS-
recovered donors were stimulated with a pool of N peptides and
were stained for intracellular IL-2 expression (Fig. 3). From Fig.
3A, it was seen that both of SARS-CoV N-protein-specific
CD4+ and CD8+ memory T cells would produce IL-2. To
establish the relationship between IL-2- and IFN-γ-producing T
cells, co-staining for IFN-γ and IL-2 expression was carried out
and analyzed by flow cytometry. The results indicated in Fig.
3B that T cells specific for N peptides of SARS-CoV could be
divided into three subsets based on IL-2 and IFN-γ expression:
single IFN-γ-secreting cells; co-expression of IL-2 and IFN-γ
cells; and single IL-2-secreting cells. The majority of T cells
specific for N peptides were single IFN-γ-secreting cells.
Compared to CD8+ T cells, higher frequency of CD4+ T cells
could express IL-2. Co-expression of IL-2 and IFN-γ cells was
rare in both CD4+ and CD8+ T cells (Fig. 3C).
Additionally, the phenotypic characteristics of N-protein-
specific CD4+ and CD8+ T cells were also investigated here.
After the stimulation with N peptides, PBMCs from three
SARS-recovered donors were stained with anti-CD4, CD8,
IFN-γ, CD45RA, CCR7 and CD62L (Fig. 4 and Table 1). The
results showed that most of IFN-γ+CD4+ T cells expressed
CCR7 (71.4–91.3%) but did not express CD45RA (73.7–
92%) and CD62L (75–76.6%). Compared with IFN-γ+CD4+
T cells, most of IFN-γ+CD8+ T cells expressed CD45RA
(57.8–73%) but did not express CCR7 (61.9–87.7%) and
CD62L (90.4–97.4%). These results suggested that IFN-
γ+CD4+T cells should be mostly contained within the
CD45RA−CCR7+CD62L− cell population, whereas IFN-
γ+CD8+ T cells should be mostly contained within the
CD45RA+CCR7−CD62L− cell population. Our results showed
that a relatively larger number of IFN-γ+CD8+ T cells were
CD45RA+CCR7− compared with IFN-γ+CD4+ T cells,
suggesting the difference of phenotype between CD4+ and
CD8+ memory T cells and also demonstrating the heteroge-
neity of memory T cells.
Mapping of dominant epitopes in N protein
To identify dominant epitopes in N protein, 57 individual
peptides were divided into six pools: pool I (N 1 to N 10), pool
II (N 11 to N 20), pool III (N 21 to N 30), pool IV (N 31 to N
40), pool V (N 41 to N 50) and pool VI (N 51 to N 57). PBMCs
from five SARS-recovered donors were stimulated with these
six peptide pools individually for 72 hour, and the levels of IFN-
γ in culture supernatants were measured by ELISA. The results
showed that PBMCs from all of five SARS-recovered
individuals had specific T-cell responses to one or more peptide
Fig. 3. Cytokine profiles of IL-2 and IFN-γ in CD4+ and CD8+ T cells in response to N peptides. PBMCs from SARS-recovered donors were stimulated with a pool of
N peptides for 6 h. The expression of IL-2 and IFN-γwas assessed by flow cytometry. (A) Dot plots show intracellular staining for IL-2 and IFN-γ in the CD8+ T cells
and CD4+ T cells. Data are representative of three independent experiments with similar results. (B) The frequency of cells expressing both IL-2 and IFN-γ in PBMCs
from SARS-recovered donors. Data are presented as the percentage of the total number of cells expressing at least one cytokine.
Fig. 4. Determination of phenotype of N-protein-specific memory T cells in SARS-recovered donors. PBMCs from SARS-recovered donors were stimulated with a
pool of N peptides for 6 h. The expression of CD45RA, CCR7 and CD62L in IFN-γ+CD4+ or IFN-γ+CD8+ T cells was assessed by flow cytometry. CD4 +CD8− or
CD4 +CD8− cells were gated and analyzed. Results shown are from one experiment performed on PBMC from a SARS patient and are representative of 3 independent
experiments from 3 SARS patients.
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Table 1
Phenotypic analysis of SARS-CoV N-specific memory T cells from donors who
have recovered from SARS 2 years after infection
Donors IFN-γ+CD4+ T IFN-γ+CD8+ T
CCR7+ CD45RA+ CD62L+ CCR7+ CD45RA+ CD62L+
07 71.4 18.0 23.4 12.3 57.8 5.2
12 76.0 8.0 25.0 38.1 73.0 9.6
13 91.3 26.3 24.0 13.8 67.4 2.6
470 H. Peng et al. / Virology 351 (2006) 466–475pools based on the production of IFN-γ. But the hierarchy of
epitope recognition varied from donor to donor. As shown in
Fig. 5A, 100% and 60% of the donors responded to pool V and
pool IV corresponding to the sequences of amino acid (aa)
residues 293–376 and 219–302 respectively, whereas frequen-
cies of other pools were below 50%. Similar results were alsoFig. 5. Specific T-cell responses to pooled peptides of the N protein in SARS-
recovered donors by ELISA and ELIspot assay. Fifty seven overlapping
individual peptides that covered the entire N protein sequence were divided into
6 pools (each pool contains 10 peptides) as described in Materials and methods.
(A) PBMCs from 5 SARS-recovered donors were stimulated with a pool of 10
peptides (1 μg/ml of each peptide) for 72 h. The culture supernatants were
collected for detection of IFN-γ by ELISA. Bars indicate mean values. (B)
PBMCs from four SARS-recovered donors were stimulated with a pool of 10
peptides (1 μg/ml of each peptide) for detection of IFN-γ expression by ELIspot
assay. PBMCs incubated with media alone were used as negative controls. The
experiments were carried out in triplicate.confirmed by the detection of IFN-γ-secreting cells using
ELIspot assay (Fig. 5B). The results showed that all of four
SARS donors responded to pool Vand the frequency of IFN-γ-
producing T cells in response to pool V was the highest among
six peptide pools. This result suggested that the pool V
contained major immunodominant epitopes corresponding to
the sequences of residues 293–376 in N protein. Therefore, the
pool V was chosen for further mapping the individual peptide
responsible for the induction of IFN-γ expression.
In the following, PBMCs from SARS-recovered donors were
tested for a single peptide screening from 10 overlapping
peptides in pool V by IFN-γ ELIspot assay. Although positive
responses were obtained with all of the peptides in one or more
donors, the highest responses (ranging from 62 to 85%) were
obtained with peptides N46 (aa 331 to 347), N47 (aa 339 to 354)
and N48 (aa 346 to 362), whereas the rest of peptides in pool V
exhibited lower responses (20%–44%) (as shown in Table 2).
Therefore, aa 331 to 362 peptide should be the major dominant
antigenic site of N protein and contain at least two different T-
cell epitopes (N46: aa 331–347 and N48: aa 346–362). Based
on ELIspot assay, IFN-γ-producing T cells specific to these two
epitopes were 25.7% of total N-protein-specific IFN-γ-
producing T cells in donor 13, 58.4% in donor 7, 38.4% in
donor 10 and 65% in donor 12, respectively (as shown in Fig.
6). Therefore, these peptides would be chosen for further
characterization.
IFN-γ response by CD4+ and CD8+ T cells for recognition
with individual peptide
As described above, peptides of N46, N47 and N48 could
effectively stimulate T-cell responses when detected with
ELIspot assay. Next, we would discuss the response of CD4+
and CD8+ T subpopulations for recognition of individual
peptide by flow cytometry. Freshly isolated PBMCs from
SARS-CoV-recovered donors were analyzed for IFN-γ expres-
sion after stimulation for 6 h in the presence or absence of
peptides N46, N47 or N48, respectively. CD8+ T and CD4+ T
cells were gated and analyzed by flow cytometry (Fig. 7A). The
frequency of SARS-CoV N-peptide-specific CD8+ T cellsTable 2
Production of IFN-γ by PBMCs from SARS-recovered donors in response to
single SARS-CoV N peptide by ELIspot
Peptides Peptide position
in protein
Number of
donors tested
Positive
response (%)
N41 293–309 4 25
N42 300–316 5 40
N43 307–323 5 20
N44 315–331 4 20
N45 323–339 6 17
N46 331–347 7 85
N47 339–354 8 62
N48 346–362 8 75
N49 354–370 5 40
N50 362–376 9 44
The peptides of pool V were used to scan SARS-recovered donors by IFN-γ
ELIspot. The number of spots in the negative control wells ranged from 0 to 2.
Fig. 7. Memory T-cell responses specific to the peptides N46, N47 or N48 by intrac
indicated peptides (N46, N47 or N48) for 6 h. The intracellular staining for IFN-γ
expression by flow cytometry (A). Results shown are representative of 3 independen
experiments for CD8+ (B) and CD4+ (C) T cells.
Fig. 6. T-cell responses to individual peptide of SARS-CoV N protein by
ELIspot assay. PBMCs from SARS-recovered donors were stimulated with a
single peptide (1 μg/ml). The production of IFN-γ was assessed by ELIspot
assay. The number of spots in the media control wells was ranged from 0 to 2.
The experiments were carried out in triplicate.
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of CD8+ T lymphocytes (Fig. 7B). However, much lower
frequencies of specific IFN-γ-producing CD4+ T cells ranging
from 0.02 to 0.29% of CD4+ T lymphocyte were detected (Fig.
7C). These data indicated that the individual peptides N46, N47
or N48 were able to induce both CD4+ and CD8+ T-cell subsets
with a predominance of CD8+ T-cell response.
Discussion
In this study, we analyzed memory T-cell responses in a
group of Chinese individuals who had clinical SARS-CoV
infection between January 2003 to May 2003. We were able to
demonstrate SARS-CoV N-protein-specific T-cell response in
all donors, and the memory T cell specific for SARS-CoV could
persist for 2 years in the absence of antigen. The N protein was
chosen because it was the most conserved protein in SARS-
CoV, and it was previously reported to be a major target for the
CTL memory response (Collisson et al., 2000; Stohlman et al.,
1995). Some studies in animals also demonstrated that the
SARS-CoV N could induce specific T-cell responses (Gao et al.,
2003; Jin et al., 2005; Kim et al., 2004; Zhu et al., 2004). In
addition, our results demonstrated that both CD4+ and CD8+Tellular staining. PBMCs from SARS-recovered donors were incubated with the
was performed. CD4+ and CD8+ T cells were gated and analyzed for IFN-γ
t experiments from 3 SARS patients. Similar results were also obtained in other
472 H. Peng et al. / Virology 351 (2006) 466–475cells were participated in SARS-CoV N-specific memory
immunity with a predominance of CD8+ T-cell memory
responses in humans. Therefore, the N protein of SARS-CoV
would be highly immunogenic and could be an important target
for SARS vaccine.
Perhaps the most important finding of this study is that N-
specific memory CD4+ and CD8+ T cells can persist in
individuals who had clinical infections with SARS-CoV 2 years
ago, in the absence of re-exposure to this pathogen. There is no
evidence of persistent SARS-CoV infection, and clinical
reinfections with SARS-CoV have never been reported. Viral
RNA can be easily detected within the first 14 days of
symptomatic SARS-CoV infection, but convalescent samples
(50 days after the onset of symptoms) are consistently PCR
negative (Xu et al., 2005). Therefore, the maintenance of N-
protein-specific T-cell memory in vivo appears to be antigen-
independent.
There are some debates regarding the role of antigen in the
maintenance of memory T cells. On one hand, periodic re-
exposure to the pathogen which serves as a natural “booster” to
the immune system is an effective way to maintain high levels
of immunity though such reinfections are usually asymptomatic
or only produce mild clinical symptoms. On the other hand, it
has been already clear that memory CD4+ T cells and memory
CD8+ T cells could persist in the absence of antigen in mice
(Murali-Krishna et al., 1999; Lau et al., 1994). Furthermore,
memory CD4+ T cells and CD8+ T cells could be maintained for
decades after smallpox vaccination in human (Hammarlund et
al., 2003). Since vaccinia virus does not cause a chronic
infection in humans and re-exposure to the virus is unlikely, the
maintenance of T-cell memory in this system also appears to be
antigen-independent. Therefore, both antigen-dependent and
antigen-independent mechanisms should be involved in sus-
taining immunological memory.
Previous studies proposed that memory T cells could be
divided into two functionally distinct subsets based on
expression of CCR7 (Sallusto et al., 1999; Seder and Ahmed,
2003). In these two subsets, CCR7− effector memory T cells
(TEM cells) would be present in the blood, spleen and
nonlymphoid tissues, whereas CCR7+ central memory T cells
(TCM cells) would be present in lymphoid, spleen and blood but
not in nonlymphoid tissues. Recent studies of both in mice and
humans have demonstrated that both cell subsets can rapidly
produce IFN-γ and TNF-α but that IL-2 production remains a
property of TEM cells following stimulation with cognate
antigen (Harari et al., 2005; Lier et al., 2003; Wherry and
Ahmed, 2004; Wills et al., 2002). Our results demonstrated that
SARS-CoV-specific memory T cells from SARS-recovered
donors rapidly produced IFN-γ and IL-2 following a short-term
stimulation with N peptides. IL-2-secreting CD4+ memory T
cells were more than those of CD8+ memory T cells. Phenotypic
analysis suggested that a higher proportion of IFN-γ+CD8+ T
cells were CD45RA+CCR7− compared with those of IFN-
γ+CD4+ T cells. These larger numbers of IFN-γ+ CD8+ T cells
were TEM cells and produced less IL-2 compared with those of
IFN-γ+CD4+ Tcells. Similar observations were also obtained in
CMV infection in which reactive CD8+ T cells expressedCD45RA during recovery (Wills et al., 2002) and a larger
number of IFN-γ+CD8+ T cells were CD45RA+ CCR7−
compared with those of IFN-γ+CD4+ T cells (Seder and
Ahmed, 2003).
As the T-cell epitopes are usually 8 to 10 aa long, the N
peptides used in our study were overlapped by 10 aa in each
peptide to minimize the possibility of missing the T-cell
epitopes of SARS N protein. The clear difference in protein
recognition among SARS-CoV immune donors suggests that
the nature and composition of the immune response against the
virus vary between individuals possibly due to the difference in
HLA types. Although the results showed that the T-cell epitopes
were scattered throughout the sequence of N protein, some
peptides were recognized more frequently than others. The
peptides that were frequently recognized by T cells were N46
(aa 331 to 347), N47 (aa 339 to 354) and N48 (aa 346 to 362).
Therefore, a cluster of peptides corresponding to aa 331 to 362
were the major dominant antigenic site on N protein and
contained at least two different T-cell epitopes (N46 and N48).
IFN-γ-producing T cells specific to these two epitopes were
from 25.7% to 65% of total N-protein-specific IFN-γ-producing
T cells in four SARS donors based on ELIspot assays.
Although SARS-CoV N protein has previously been tested
for induction of T-cell responses in animals (Gao et al., 2003;
Jin et al., 2005; Kim et al., 2004; Zhao et al., 2005; Zhu et al.,
2004), our data provide the first evidence in which the T-cell
epitopes of N protein recognized by human T cells were
mapped. Our results suggest that the C-terminal end of N
protein may be highly immunogenic. This had been confirmed
by Kim et al. who observed a strong T-cell response to the N
peptides at aa 346 to 354 when mice were immunized with N
protein (Kim et al., 2004). These peptides were overlapped with
the peptide N47 and peptide N48 in our study. Like other CoVs,
SARS-CoV N proteins clearly contain multiple immunodomi-
nant epitopes and antigenic sites (Stohlman et al., 1994).
Several groups have been extensively studied for B-cell
epitopes of N protein in SARS patients (Chen et al., 2004; He
et al., 2004; Liang et al., 2005; Lin et al., 2003; Zhong et al.,
2005). He and his co-workers demonstrated that two major
immunodominant epitopes that reacted with more than 75% of
sera from SARS patients were localized at the C-terminal and
middle regions, corresponding to aa 362 to 412 and 153 to 178,
respectively (He et al., 2004). This suggests that B cells and T
cells target to distinct regions of the N protein during the
immune response to SARS-CoV. This may be an important
consideration in the design of effective vaccines capable of
eliciting both humoral and cellular responses.
The frequencies of SARS-CoV-specific memory T cells
reported here are comparable to the frequencies of T cell
specific for dominant influenza A virus epitopes (Lalvani et al.,
1997). In a previous study, the highest frequencies of memory T
cells specific for dominant influenza Avirus epitopes on the M1
and NP proteins ranged from 9 to 286/106 PBMCs and from 15
to 67/106 PBMCs, respectively (Lalvani et al., 1997; Jameson et
al., 1998). The highest frequencies of SARS-CoV N46-specific
T cells measured in our study were 12–90/106 PBMCs.
Influenza virus can periodically reinfect individuals with
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T-cell responses. However, periodic exposures to SARS-CoV
have never occurred and secondary infections have never been
reported for this. Thus, the memory T-cell response of SARS-
CoV is unlikely to be effectively boosted. Overall, the
frequencies of SARS-CoV-specific memory T cells measured
in our study are comparable to those measured in other acute
virus infections such as influenza. This system could provide a
model system of T-cell memory to study the maintenance of
antiviral T-cell memory in humans after an acute infection in the
absence of antigen.
In conclusion, our study has demonstrated that both CD4+
and CD8+ T cells are involved in SARS-CoV N-specific
memory immunity and that the memory T-cell responses
specific for SARS-CoV have been maintained for 2 years in
the absence of antigen. We also find that peptide 331–362 is the
most dominant antigen site of the N protein and contains at least
two different T-cell epitopes (N46: aa 331–347 and N48: aa
346–362). The identification of specific T-cell responses in
SARS patients is essential for understanding the mechanism
involved in recovery from infection and the pathology of
infection. This information should be useful for the design of
effective vaccines against SARS-CoV and for fundamental
studies of human T-cell memory.
Materials and methods
Subjects
Fourteen recovered SARS individuals (7 men and 7 women,
aged 20 to 37) were obtained from the Second Affiliated
Hospital of Sun Yat-sen University and Guangdong Provincial
Hospital of Traditional Chinese Medicine, Guangzhou, Guang-
dong, China, respectively. All of the donors had been diagnosed
as SARS patients based on clinical examination during the
period of January to May 2003. The diagnostic criteria for
SARS-CoV infection followed the World Health Organization
definition of SARS (Hoey, 2003). The diagnosis of SARS-CoV
infection was further confirmed by serological detection of
SARS-CoV-specific antibodies (Huang et al., 2005; Wu et al.,
2004). Three normal subjects without any contact history with
SARS patients were used as controls.
Synthetic peptides
Fifty-seven synthetic peptides that spanned the entire
sequence of the SARS-CoV N protein were kindly provided
by Drs. Koup and Bailer at the Vaccine Research Center of
National Institute of Allergy and Infectious Diseases
(NIAID), National Institutes of Health (NIH), USA. The
peptides were 15–20 mers overlapped by 10 amino acids
and named as N1 through N57. In order to map epitopes,
57 peptides were divided into six pools: pool I, N1 to N10;
pool II, N11 to N20, pool III, N21 to N30; pool IV, N31 to
N40; pool V, N41 to N50; and pool VI, N51 to N57. These
pools and single peptide were used in the subsequent
experiments.Isolation of PBMCs
Peripheral blood mononuclear cells (PBMCs) were isolated
from heparinized venous blood by Ficoll-Hypaque density
gradient centrifugation. Cells were washed twice with RPMI
1640 (GiBco) and suspended in complete culture medium
(RPMI 1640 containing 10% fetal calf serum, 100 U of
penicillin per ml, 100 mg of streptomycin per ml).
IFN-γ assay by ELISA
PBMCs were seeded into the wells of 96-well culture plates
(Becton Dickinson) (2 × 105 cells/well) in triplicate. Peptides
and costimulatory mAbs to CD28 (BD Pharmingen) and CD49d
(BD Pharmingen) were added each at 1 μg/ml to the wells. In
addition, PBMCs stimulated with mAbs to CD3 and CD28 were
used as positive controls and PBMCs unstimulated as negative
controls. The plates were incubated for 72 h at 37 °C in a
humidified atmosphere containing 5% CO2 and 95% air.
Supernatants were collected, and the level of IFN-γ was
measured by ELISA kit (R&D) according to the manufacturer's
instruction. The detection limit of the IFN-γ assay kit was
15 pg/ml.
IFN-γ ELIspot
ELIspot assay kit for IFN-γ was purchased from BD
Biosciences and performed as described (Lalvani et al., 1997).
Briefly, 96-well plates (Millipore) were coated with anti-IFN-
γ mAb at 4 °C overnight. The plates were washed three times
before blocking with complete culture medium. Fresh PBMCs
were plated at 2 × 105 cells per well in triplicate. Peptides and
costimulatory mAbs to CD28 and CD49d were added each at
1 μg/ml. PBMCs stimulated with CD3 and CD28 (1 μg/ml)
mAbs were used as positive controls, and PBMCs were not
stimulated as negative controls. After incubation for 20 h at
37 °C, the cells were removed and incubated with biotinylated
anti-human IFN-γ detection antibody for 2 h at room temper-
ature. After washing, wells were developed for 1 h with strep-
tavidin–HRP and incubated with substrate reagent according to
the manufacturer's protocol. Spot-forming cells (SFC) were
detected with ELIspot image analysis system (Sage Creation).
The frequency of IFN-γ-producing cells was calculated as the
number of spots/number of total PBMCs per well and was
adjusted as the number of IFN-γ-producing cells/106 PBMCs.
The number of spots in negative control wells was at a range of
0–2 spots.
Intracellular cytokine staining and flow cytometry
Intracellular IFN-γ and IL-2 expression was assessed as
previously described (Hoffmeister et al., 2003). 1 × 106 cells
(PBMCs) were placed into polystyrene tissue culture tubes
(Becton Dickinson) with 1 ml of complete medium (CM) and
were stimulated with peptides plus costimulatory mAbs as
described above. Culture tubes were incubated at 37 °C in a
humidified 5% CO2 atmosphere for 6 h. Brefeldin A (Sigma-
474 H. Peng et al. / Virology 351 (2006) 466–475Aldrich) was added to cells at a final concentration of 10 μg/ml
to prevent secretion of cytokines. After incubation, the cells
were harvested and washed twice with PBS containing 0.1%
BSA plus 0.05% sodium azide. Cell phenotype was determined
by cell surface staining with PerCP-labeled anti-CD4, PerCP-
labeled anti-CD8, FITC-labeled anti-CD45RA, PE-labeled anti-
CCR7 and PE-labeled anti-CD62L mAbs (BD Pharmingen) at 4
°C for 30 min. Intracellular IFN-γ or IL-2 detection used APC-
labeled anti-IFN- and PE-labeled anti-IL-2 (BD Pharmingen).
Briefly, cells were fixed with PFA 4% for 8 min, washed in
PBS–BSA–0.1% saponin buffer and incubated for 1 h with
0.1% saponin buffer. Cells were washed with PBS–BSA–0.1%
saponin buffer and stained with the labeled Abs at 4 °C for
30 min. Data acquisition was performed on a flow cytometer
(FACS calibur). Data were analyzed using CellQuest 4.3
software (Becton Dickinson).Acknowledgments
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